Surgeon

Big Sky Medical Celebrates Lease Renewal In Premier Dallas Location

Retrieved on: 
Monday, March 11, 2024

DALLAS, March 11, 2024 (GLOBE NEWSWIRE) -- Big Sky Medical is excited to announce the successful lease renewal with Dallas Plastic Surgery Institute (DPSI) for over 45,000rsf of space in its premier building, The Pyramids at Park Lane South Tower.

Key Points: 
  • DALLAS, March 11, 2024 (GLOBE NEWSWIRE) -- Big Sky Medical is excited to announce the successful lease renewal with Dallas Plastic Surgery Institute (DPSI) for over 45,000rsf of space in its premier building, The Pyramids at Park Lane South Tower.
  • Big Sky worked with OMS Strategic Advisors as brokers for the lease renewal.
  • “Where many landlords lack the creativity and willingness to address the needs of their tenants, Big Sky excels.
  • “Big Sky is excited for the continued partnership with Dallas Plastic Surgery Institute and their commitment to the Pyramids location.” – Amenemopé McKinney Big Sky’s Portfolio Manager.

Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases

Retrieved on: 
Monday, March 11, 2024

PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.

Key Points: 
  • PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.
  • “MicroMatrix Flex has allowed me to expand how I use UBM technology in complex wound reconstruction procedures,” said Dr. Aaron Moore, acute care surgeon, Mercy Health - St. Vincent Medical Center.
  • During this period, UBM has been published in more than 200 pre-clinical and clinical publications.
  • “We’re excited to be adding MicroMatrix Flex to our market-leading portfolio of dermal matrices,” commented Steve Powick, senior vice president, Global Marketing, Tissue Technologies Product Division.

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

Retrieved on: 
Thursday, March 7, 2024

The Company remains on track for a clearance decision in the first half of 2024.

Key Points: 
  • The Company remains on track for a clearance decision in the first half of 2024.
  • "In 2023, we completed the groundwork for our flagship product, CanGarooRM, resulting in a high-quality submission to FDA.
  • Elutia expects the FDA's clearance decision in the first half of 2024 and is preparing for commercial launch.
  • Elutia will host a conference call today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial results and performance.

Accelus President & CEO Kevin McGann to Present at LSI USA '24 Conference

Retrieved on: 
Tuesday, March 5, 2024

McGann’s presentation will provide an unparalleled opportunity for industry participants to engage with the company.

Key Points: 
  • McGann’s presentation will provide an unparalleled opportunity for industry participants to engage with the company.
  • Accelus has made significant strides under McGann’s leadership, from the sale of its Remi spine robot to Alphatec for $55 million to its recent $20 million funding from Symbiotic Capital.
  • “The LSI USA ’24 conference presents a valuable opportunity for attendees to discover how Accelus’s advancements in expandable spinal implants are providing minimally invasive yet maximally effective solutions for spinal fusion,” McGann said.
  • Attendees of the LSI USA '24 conference are invited to join Kevin McGann's presentation on March 21st at 2:40 p.m. in Track 2 to learn more about Accelus's transformative technologies and strategic vision for the future of spine care.

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Retrieved on: 
Monday, March 4, 2024

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).

Key Points: 
  • WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”).
  • The new addition to the RESPONSE™ family includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.
  • As an adjunct to the foundational RESPONSE™ Scoliosis System, the Rib and Pelvic system is compatible with 5.5/6.0 and 4.5/5.0 RESPONSE™ Systems, allowing surgeons to treat the entire spectrum of patients with scoliosis.
  • Greg Odle, President of the OrthoPediatrics’ Scoliosis Division echoed his excitement for the launch of this new system, saying “We are excited to enter the Early Onset Scoliosis treatment market with the RESPONSE™ Rib & Pelvic System.

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on: 
Monday, March 4, 2024

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points: 
  • Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
  • Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
  • Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
  • We look forward to introducing Nociscan to a growing number of physicians and patients.”
    Access to the publication can be found here.

Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions

Retrieved on: 
Monday, March 4, 2024

Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day.

Key Points: 
  • The command unit has a key role in identifying innovative pain management solutions for Veterans Administration (VA) and Department of Defense (DoD) patients and uses.
  • SofPulse®, along with its VA reseller, Academy Medical Inc., is planning to showcase SofPulse® and its non-evasive, drug-free pain management solution to the VA and military attendees.
  • SofPulse® featured by Academy Medical at USAMRDC Vendor Day, offers extended exposure for the opportunity to present and demonstrate its innovative pain management solutions to multiple organizations at one time.
  • Integrating SofPulse® into its post-operative pain management protocols, the VA can improve the quality of care and enhance the well-being of veterans nationwide.

FSIS Commends Appointment of Dr. Kis Robertson Hale as Chief Veterinarian Officer of USPHS

Retrieved on: 
Friday, March 1, 2024

WASHINGTON, March 01, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) commends the appointment by the U.S. Public Health Service (USPHS) of Dr. Kis Robertson Hale as Chief Veterinarian Officer.

Key Points: 
  • WASHINGTON, March 01, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) commends the appointment by the U.S. Public Health Service (USPHS) of Dr. Kis Robertson Hale as Chief Veterinarian Officer.
  • Dr. Robertson Hale is a Rear Admiral in the USPHS Commissioned Corps and serves as FSIS’ Chief Public Health Veterinarian and Deputy Assistant Administrator of the Office of Public Health Science, positions that she will continue to hold.
  • In her new appointment as Chief Veterinarian Officer of the USPHS, Dr. Robertson Hale will provide expert guidance to the Office of the Surgeon General and the U.S. Department of Health and Human Services on matters related to veterinary recruitment, assignment, deployment, retention and career development.
  • Robertson Hale’s appointment as Chief Veterinarian Officer by the U.S.

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

Retrieved on: 
Thursday, February 29, 2024

Gross profit for the quarter ended December 31, 2023 was $48.5 million, or 75% of net revenue, compared to $38.2 million, or 73% of net revenue, for the fourth quarter of 2022.

Key Points: 
  • Gross profit for the quarter ended December 31, 2023 was $48.5 million, or 75% of net revenue, compared to $38.2 million, or 73% of net revenue, for the fourth quarter of 2022.
  • Total operating expenses for the quarter ended December 31, 2023 were $35.8 million, compared to $32.2 million for the same period in 2022.
  • Non-GAAP adjusted EBITDA for the quarter ended December 31, 2023 was $22.3 million, or 34% of net revenue, compared to $14.9 million, or 28% of net revenue, for the fourth quarter of 2022.
  • Total net revenue for the year ended December 31, 2023 was $197.5 million, compared to $164.4 million in 2022.

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on: 
Tuesday, February 27, 2024

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points: 
  • “I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
    Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
  • Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
  • Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
  • I applaud AOFAS for taking that initiative with these awards.”
    Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.